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Abstract
Background: Telehealth has the potential to improve asthma management through regular monitoring of lung
function and/or asthma symptoms by health professionals in conjunction with feedback to patients. Although the
benefits of telehealth for improving asthma management have been extensively studied, the feasibility of telehealth
for supporting asthma management in pregnant women has not been investigated. This study aims to evaluate the
use of telehealth for remotely monitoring lung function and optimising asthma control during pregnancy.
Methods: A randomised controlled trial comparing usual care with a telehealth program (MASTERY©) has been
conducted. The intervention comprised a mobile application – Breathe-easy© supported by a Bluetooth-enabled
handheld device (COPD-6®), which was used for self-monitoring of lung function (FEV1, FEV6) twice daily, and
recording asthma symptoms and medication usage weekly; and a written asthma action plan (WAAP). The primary
outcome measure is change in asthma control measured using the Asthma Control Questionnaire (ACQ).
Secondary outcomes include changes in mini-Asthma Quality of Life Questionnaire (mAQLQ) score, lung function,
asthma-related health visits, days off work/study, and oral corticosteroid use. Outcome data were collected at
baseline, 3 months and 6 months by a research assistant masked to group allocation. Maternal and neonatal
outcomes were also collected post-partum.
Discussion: This is the first study to evaluate the application of telehealth to optimize asthma management in
pregnant women. If effective, this telehealth program could improve asthma self-management by pregnant women
which may reduce the maternal and fetal risks of poorly controlled asthma during pregnancy.
Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN 12613000800729) 17 July 2013
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Background
Asthma is the most common obstructive pulmonary dis-
ease that occurs during pregnancy and may complicate
pregnancy [1–4]. Previous studies have demonstrated that
asthma during pregnancy improves in slightly more than
a quarter of patients, but worsens in slightly more than
one-third, and remains unchanged in one-third [5]. Poorly
controlled asthma increases the risk of poor outcomes such
as pre-eclampsia, fetal growth restriction, preterm birth and
need for caesarean delivery [6–9]. Given the lifelong health
decrements associated with these outcomes, an approach
to optimise monitoring and treatment of asthma could have
major short and long term public health benefits.
Education and regular monitoring by a pharmacist-
led multidisciplinary team has been shown to improve
asthma control during pregnancy [10]. Asthma man-
agement programs for pregnant women which involve
regular monitoring of lung function and assessment
of asthma symptoms appear to be effective in redu-
cing asthma exacerbations [11, 12]. However, further
studies are required to determine the most effective
and safe interventions for managing asthma in pregnancy
to improve maternal and neonatal outcomes [12].
Better asthma control can be achieved if patients are in-
volved in self-management. This includes self-monitoring
of asthma symptoms or lung function and following written
asthma action plans while maintaining regular contact with
their health professionals [13]. Telehealth supports asthma
management through patient education, adherence sup-
port, telephone follow-up and remote monitoring [14]. Tel-
ehealth interventions have shown significant clinical
improvement and potential benefits in patients with
asthma, including: reduced time to access healthcare ser-
vices and reduced cost linked to travelling; earlier detec-
tion of worsening asthma (e.g. exacerbations), and
reduced healthcare visits/hospitalisations due to asthma
[15–18]. Lung function data derived from telehealth as-
sessment studies were comparable to those collected
under supervision by healthcare professionals and thus
valid [19, 20]. Telehealth programs also appeared to be
feasible for asthma patients, as compliance with monitor-
ing was high and most patients found the equipment
easy to use [21].
Telehealth studies show potential benefits for asthma
management in the general population [22]. However
the feasibility of telehealth for supporting asthma man-
agement in pregnant women has not been investigated
to date. Pregnant women with asthma are young and are
likely to be willing to use new technology to assist self-
management of their asthma. Hence, the present study
will examine the potential for enhanced asthma manage-
ment in pregnancy through a telehealth program.
The study aims to evaluate the efficacy of a telehealth
intervention supported by a handheld respiratory device
and a written asthma action plan (WAAP) for manage-
ment of asthma in improving asthma control during
pregnancy. We hypothesised that the telehealth inter-
vention group will have better asthma control as mea-
sured by the Asthma Control Questionnaire (ACQ)




Participants were recruited when attending scheduled
antenatal visits at two large maternity hospitals in
Melbourne, Australia (Mercy Hospital for Women and
The Royal Women’s Hospital); each hospital has ap-
proximately 6000 births per year.
Study design
The study was designed as a prospective multi-centre
single-blinded randomised controlled trial (RCT) with
outcome assessors masked to group allocation at follow-
up assessments. The flow of participants is illustrated in
Fig. 1. The total duration of the intervention was
6–8 months depending on timing of the first antenatal
visit and enrolment in the study. Both groups were
followed up throughout pregnancy and the outcomes are
being compared at three and six months from baseline
to evaluate the efficacy of the intervention.
Inclusion and exclusion criteria
Eligibility for this trial included pregnant women with
asthma who had used any inhaled bronchodilator or
anti-inflammatory agent for asthma within the previous
12 months, were attending antenatal clinics in first or
second trimester, aged 18 years or older and able to
communicate in English. Those under specialist care for
severe/difficult asthma were excluded. Women who are
not already in possession of or have not used a smart
mobile phone were considered ineligible to participate.
This was confirmed by directly asking pregnant women
about their mobile phone usage.
Trial recruitment
The following methods of identification and recruitment
of participants were used:
1. One of the researchers (EZ) or research staff
searched the outpatient files and screened the
medical records of pregnant women with asthma
scheduled to have a clinic visit on the following day
by reviewing GP referral letters and/or notes from
previous clinic consultations. Eligible women were
approached for recruitment after clinic visit
completion. On each day the researcher/research
staff also searched for potential participants by
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screening medical records of women who were
reviewed by the midwives or medical staff in the
antenatal clinics.
2. At one of the sites (the Mercy Hospital for Women),
a letter of invitation including a brief explanation of
the study together with their antenatal appointment
letter was posted to all pregnant women newly
registered with the antenatal clinic. At their first
clinic visit, the researcher approached each eligible
woman and sought interest in participation.
3. Advertising posters about the study were placed in the
antenatal clinics of participating hospitals and on the
websites of the National Asthma Council and the
Asthma Foundation of Victoria. Participant explanatory
statements and expression of interest forms were also
made available. Potential participants had access to the
information and were asked to leave their contact
details to allow one of the researchers to contact them.
If the woman agreed to participate, written informed
consent was sought.
Group allocation
Recruited participants were allocated to intervention or
control groups on a 1:1 basis, stratified by their asthma
severity. Asthma severity was assessed in accordance with
the National Asthma Council Australia (NAC) Asthma
Handbook classification based on their current asthma
medications and symptoms [23]. Participants were classi-
fied into two groups: 1) Intermittent – mild asthma: using
relievers only (e.g. salbutamol); 2) moderate – severe
asthma: using any regular inhaled corticosteroids/ pre-
venters/ symptom controllers or their combinations.
Allocation was concealed using the sealed opaque enve-
lope technique. Random blocks of four and six were
chosen and random numbers were generated using a ran-
dom allocation software program [24] by an external re-
searcher not involved in the study. The allocation
sequence was known to this researcher only. At the time
of recruitment, the investigator (EZ) opened the num-
bered envelope and allocated each participant to the con-
trol (usual care) group or the intervention (MASTERY)
group. The outcome assessors were masked to the partici-
pant group allocation at follow-up assessments.
Control and intervention group
Intervention: MASTERY group
The trial evaluated an intervention involving a telehealth
program supported by a Bluetooth-enabled handheld
spirometer COPD-6® (model number 4000, Vitalograph
Fig. 1 Participant flow diagram
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Ltd, Ennis, Ireland) and a WAAP. Women allocated to
the intervention group were provided with a COPD-6®
and a loaned smart mobile phone with the specifically
designed Breathe-easy© application installed on it. Each
participant measured their lung function (FEV1 and
FEV6) daily using the COPD-6® device and recorded
asthma symptoms and asthma medication usage in the
Breathe-easy© application weekly. The daily lung func-
tion data were uploaded to a central server where the re-
searchers, participants and their health professionals had
secure access to the data. The participants’ health pro-
fessionals were contacted by one of the researchers, a
trained asthma educator (EZ), if any medication changes
or unscheduled asthma-related visits were needed.
A WAAP consistent with NAC guidelines was de-
signed for each participant based on information ob-
tained at baseline. The WAAP contained instructions on
which medications to take when feeling well, how to rec-
ognise worsening asthma, what to do when symptoms
are getting worse and what to do in the event of an
acute attack, including a first aid plan. Each participant
received an automated weekly message regarding their
asthma status based on the Breathe-easy© algorithm that
was designed based on NAC [23] and Global Initiative
for Asthma (GINA) guidelines [25] (Additional file 1:
Table S1). An automated weekly message of overall
asthma control status was displayed as ‘well-controlled’
(score 0, green zone), or ‘not well controlled’ (score 5,
yellow zone and score 6, orange zone) to encourage par-
ticipants to follow their agreed asthma action plan and/
or contact their health professional the next working day
if there was no improvement. If the asthma control sta-
tus was displayed as ‘very poorly controlled’ (score 7–15,
red zone), patients were prompted to follow their agreed
asthma action plan and contact their health professional
on the same day. The flow of the study is described in
Fig. 2 and the details of the intervention are illustrated
in Fig. 3.
Control: usual care group
Women allocated to the control group received the usual
medical care provided by the antenatal clinics and/or their
health professionals. This included their regular weekly to
monthly antenatal visits depending on their trimester and
other complications. If during follow up, it was apparent
that their asthma control deteriorated since prior assess-
ment (for example; using their reliever three or more times
a week, needing to increase their preventer dose), the par-
ticipant was advised by the research team to contact their
health professionals. The control group was also given a
summarised version of the “Asthma and Pregnancy” bro-
chure from the NAC which explained about asthma in
pregnancy including first aid and emergency assistance
number to use for any concerns regarding their asthma.
Outcome measures
The primary outcome measure was change in asthma
control as measured by the Juniper Asthma Control
Questionnaire (ACQ - 7) [26]. Secondary outcomes in-
cluded changes in Juniper’s mini Asthma Quality of Life
Questionnaire (mAQLQ) score [27], lung function
(FEV1 and FEV6), self-reported exacerbations (symptoms
requiring bronchodilators), asthma-related health visits,
days off work/study related to asthma, and oral cortico-
steroid use. Lung function testing (pre-bronchodilator)
was performed by trained research assistants using Easy-
One™ Worldspirometer (ndd Medizintechnik AG,
Zurich, Switzerland). Maternal and neonatal outcomes
data collected are the gestational age of the baby at de-
livery, development of any antenatal complications such
as gestational diabetes, hypertensive disorders of preg-
nancy, fetal growth restriction, antepartum hemorrhage,
and delivery details. Neonatal outcomes collected at de-
livery include birth weight centile, birth length, head cir-
cumference, and Appearance Pulse Grimace Activity and
Respiratory (APGAR) scores at 1 and 5 min after deliv-
ery. Birth weight centiles were calculated using
www.gestation.net/grow-au.aspx, which adjusted for ma-
ternal characteristics including height, weight, ethnicity,
parity and fetal gender.
Data collection and follow-up
ACQ, mAQLQ scores, asthma-related health visits,
asthma-related days off work/study, and oral cortico-
steroid use were collected at baseline, 3 months and
6 months from baseline to allow comparisons. Identi-
cal data collection forms were used for both groups.
Maternal and neonatal outcomes data were collected
shortly after delivery by reviewing medical records.
The assessors responsible for collecting outcome data
at three and six months were masked to the partici-
pant group allocation.
Sample size
A sample size of 28 per arm is sufficient to detect the mini-
mum clinically important difference in ACQ score of 0.5 or
more between treatment groups using a standard deviation
of 0.66 [10, 28, 29]. We estimate, conservatively, that by
3 months, there will be an improvement of at least 0.5 in
the ACQ score in the intervention arm and that the control
arm could exhibit a very small improvement or no im-
provement at all in the ACQ score. If these improvements
are sustained at 6 months, then with 28 evaluable subjects
in each arm, and assuming an independence model for
measurement variation, and an intraclass correlation of 0.5
(equivalent to a within patient variance of 0.218 when the
total variance is 0.662 = 0.436), the F-test, conducted at the
5 % significance level will have at least 80 % power to detect
a treatment by time interaction effect. If these conjectured
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Fig 2 Flow chart of the study
Fig 3 The MASTERY© trial design
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improvements by month 3 are not durable and the scores
return, on average, to their baseline levels at 6 months, then
both the F-test for the interaction and the two-sided t-test
comparing the two arms at month 3 at the 5 % level of sig-
nificance will continue to have at least 80 % power. To
allow for approximately 25 % attrition, the target sample
size has been inflated from 28 per arm to 36 participants
per arm. The study is, however, not powered to detect dif-
ferences in the secondary outcomes.
Data analysis
All analyses will be performed using SAS version 9.4
(SAS Institute, Cary, NC, USA) and SPSS version 19.0
(IBM SPSS Statistics for Windows, Armonk, NY). The
baseline characteristics of the two groups will be com-
pared using Student’s t-test for normally distributed con-
tinuous variables, Mann-Whitney ‘U’ test for non-
normally distributed continuous variables and chi-square
or Fisher’s exact test as appropriate for categorical vari-
ables. The primary analysis will be performed according
to the intention to treat (ITT) principle on the “full ana-
lysis set”.
Primary inferential analyses will be conducted using a
mixed effects model for the ITT population. This model
will include treatment group and time as fixed effects
with an interaction between treatment and time to ascer-
tain if the groups behave differently over time. All ob-
served data will be included in the analysis, with the
mixed-effects models, fitted by residual maximum likeli-
hood (REML) assuming non-informative dropout such
that the probability of dropout may depend on a partici-
pant’s previous response but not on current or future re-
sponses. In supportive analyses, changes in the primary
outcome from baseline to 3 and 6 months will be com-
pared between groups using linear regression modelling
adjusting for baseline scores. Baseline demographic and
clinical factors that appear to be different will be in-
cluded as potential covariates in all regression models.
We will also compare the proportion of participants
whose ACQ score improves more than 0.5 (MCID) over
the study period, the proportion in whom asthma
remained “not well controlled’ (ACQ score 1.5 or
greater) and those whose asthma was “well controlled”
(ACQ score less than 1.5) at each time point [26]. Sec-
ondary outcomes will be summarised using descriptive
statistics and analyses will be performed using the
methods described above.
Ethical aspects
The study has been approved by the human research ethics
committees of Monash University, Mercy Hospital for
Women and The Royal Women’s Hospital. All participants
provide written informed consent at the time of enrolment.
The study has been registered with the Australian New
Zealand Clinical Trials Registry: ACTRN12613000800729.
Discussion
Innovative solutions are needed to support self-
management and to improve asthma control during
pregnancy. The MASTERY trial is designed to evaluate a
telehealth program aimed at helping pregnant women
with asthma to monitor their lung function and better
manage their asthma during pregnancy. The Vitalograph
COPD-6® is designed to enable the lung function data to
be transmitted automatically via a Bluetooth connection
to another enabled device (e.g. phone, computer). In our
study, the Breathe-easy© application installed on a smart
phone acquires the data and transmits via internet to a
secure website, which can be accessed only by patients
and other authorized personnel.
Automatic transmission can minimise the risk of er-
rors when data are entered/reported manually. The
Breathe-easy© application has been developed to record
lung function data, asthma symptoms and medication
usage and provides a user-friendly interface through a
smart mobile phone. Recording symptoms as part of
asthma management is known to reduce costs associated
with unplanned hospitalisation and improved quality of
life in asthma patients [13, 27, 28].
Daily recording of lung function and weekly assess-
ment of asthma symptoms could allow women to
recognize early worsening of their asthma control. Par-
ticipants in the intervention group were provided with a
WAAP as it was part of the algorithm of the telehealth
intervention (MASTERY). The automated messages sent
to each participant in the intervention group contained
feedback regarding their asthma control/condition and
asked them to refer to their individualised WAAP for
further management. The individualised WAAP de-
signed for each woman provided clear guidelines in
terms of actions to be taken in case of worsening
asthma. Although the WAAP alone may be effective in
achieving asthma control, the telehealth (Breathe-easy©)
app had additional features for monitoring and record-
ing symptoms and lung function to give instant feedback
to participants about their asthma status using an algo-
rithm based on an individualized WAAP.
The proposed intervention has the potential to identify
worsening asthma control early and prevent asthma ex-
acerbations during pregnancy by regularly monitoring
lung function and asthma symptoms. This may trans-
lated to reduce health care costs through fewer asthma-
related unplanned medical and emergency department
visits. If the intervention is efficacious, this could poten-
tially influence clinical practice and health policy. The
Breathe-easy© application could be made widely
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applicable for routine clinical use, particularly for those
with chronic respiratory conditions.
Trial status
At the time of manuscript submission, participant re-
cruitment, randomisation and follow-ups have been
completed. The data analysis is currently in progress.
Additional file
Additional file 1: Table S1. The Breathe-easy© algorithm.
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